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T obacco smoking is the number one preventable cause of death worldwide. Death rates document-
ed in the UK have shown that more than 
120,000 patients per year have died be-
cause of smoking.1,2 Financially, the bud-
get required in order to treat the diseas-
es and the medical conditions developed 
as a result of tobacco smoking is calcu-
lated to cost the National Health System 
up to £1.7 billion per year.1,2 As smoking 
is a modifiable risk factor for cardiovascu-
lar disease, early and total cessation could 
prevent morbidity and mortality. Smoking 
activates platelets and increases their ad-
hesion, it causes malfunction or damage 
to the vascular endothelium, and it also 
increases the fluidity and levels of fibrin-
ogen.3 Smoking also causes atherosclero-
sis, leading to myocardial infarction, an-
gina, sudden death, stroke, and intermit-
tent claudication.4,5 A number of studies 
have shown that legislation to ban smok-
ing in of public places has led to a reduc-
tion in the incidence of myocardial infarc-
tion, especially among young people and 
non-smokers.3
Tobacco smokers face difficulties 
when they decide to discontinue, as the 
dependency on nicotine makes quitting 
hard without help and support. Smoking 
cessation services are services that en-
courage smokers to use a combination of 
pharmacological aids and psychological 
support in order to stop this habit more 
effectively. Educating smokers about the 
importance of not smoking is the first step 
in their long-term effort to give up the 
habit. This is why health care profession-
als, and more specifically pharmacists, 
should offer psychological support, help 
patients in their decision to quit smok-
ing, inform them, and make sure that they 
understand the harmful effects of smok-
ing, as well as the benefits of giving up. 
Once a patient has taken the important 
decision to quit smoking, there are three 
methods to help the implementation of 
that decision: nicotine replacement thera-
py (NRT), non-nicotine pharmacotherapy 
(Bupropion, Varenicline), and electron-
ic cigarettes.3-8 Smoking cessation servic-
es were found to be cost-effective,8 but 
they necessitate approaches that could 
educate a large percentage of the general 
population. Community pharmacists and 
pharmacy personnel, who include phar-
macy assistants, pharmacy technicians 
and trainees, could be the number one ac-
cessible option for patients who want to 
stop smoking.3,6-7,9 In addition, published 
data have reported that pharmacists and 
pharmacy staff could play an active role 
in smoking cessation services, for exam-
ple by providing education and counsel-
ling on the available NRT products (e.g. 
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patches), as well as suggesting lifestyle and behav-
ioural changes.
The principal purpose of this literature review 
is to evaluate the existing accessible published da-
ta regarding the training, interventions, outcomes, 
and cost-effectiveness of pharmacy-led smoking ces-
sation services within the UK. We performed a re-
view and examination of the information contained 
in each study concerning ways in which pharmacy-
led smoking cessation services can be enhanced in 
the future.
Materials and Methods
This literature review was conducted according to the 
regulations and recommendations of the Centre for 
Reviews and Dissemination’s guidance for undertak-
ing Systematic Reviews.10
Search approach
The study search was conducted between 9th Oc-
tober and 9th December, 2014, using the following 
electronic search engines: Science Direct, Google 
Scholar, Web of Knowledge, PubMed, NCBI, Sco-
pus, and The Cochrane Library. These particular 
search engines were selected for the purpose of this 
review because of their comprehensive amount of 
available data related to the topic of preventative 
medicine and clinical pharmacy, as well as health sci-
ences. The keywords used for the purpose of this re-
view were as follows: preventative medicine, clinical 
pharmacy, smoking, England, Scotland, UK, smok-
ing cessation, smoking cessation products, communi-
ty pharmacies interventions, role of the pharmacists 
in smoking cessation, pharmacy staff and smoking, 
healthy living pharmacies, outcomes of smoking ces-
sation services, cost-effectiveness, and smoking ces-
sation services.
Study eligibility criteria
The selection criteria were based on the design of the 
study searched. This literature review included obser-
vational studies and randomised controlled trials re-
ferring to any smoking cessation service offered by 
pharmacists or any other member of staff within the 
community pharmacy setting. Furthermore, the se-
lection criteria were based on studies that recruited 
smokers, covered the cost-effectiveness of the phar-
macy services, and were related to quitting smoking 
as well as the interventions and the outcomes (total 
avoidance and regression).
Inclusion criteria
The inclusion criteria assigned had geographical and 
time limits, which meant that the studies evaluated 
data derived from the UK and were conducted be-
tween 1990 and 2014. In addition, the studies chosen 
in this paper were specifically related to smoking ces-
sation services offered within community pharmacies. 
The use of the English language was also a set crite-
rion.
Case studies chosen and data extraction approach
The inclusion and exclusion criteria were applied, and 
one assessor (AP) screened all suitable studies for the 
appropriate documentation. Key points of informa-
tion were obtained from the studies. These included the 
study authors, year of publication, background of the 
study, the methodology proposed, the country of origin, 
the features of the participants and the main outcome.
Results
Literature search and study choice
Three hundred and two citations were acknowledged, 
of which 25 were duplicated and 92 were not appro-
priate. The flow chart in Figure 1 demonstrates the 
article assessment and the choice procedure. Articles 
were assessed through their abstracts, and 185 were 
excluded, leaving 37 full-text articles to be screened 
for appropriateness. Finally, six full-text articles met 
the criteria set.
Features of the selected studies
After the selection procedure, six studies were incor-
porated in this review, covering 6528 participants. 
This review evaluated two observational studies and 
four randomised controlled trials, all conducted in 
the UK. Additional information on the study fea-
tures and strategy, number and characteristics of the 
participants, as well as the monitoring period, are 
shown in Table 1. Of the six studies comprising the 
review, two investigated the interventions and out-
comes of smoking cessation services in the commu-
nity pharmacy setting, one showed the cost-effec-
tiveness outcomes of a pharmacy-led group smoking 
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Table 1. UK study features.
Authors Year Design Participants Characteristics of the sample Monitoring period
Bauld et al.16 2011 Observational
study
1785 smokers - 52 weeks
Boyd et al.15 2009 Observational
study
1979 smokers Age range: 16 or above
Female sample > Male
No. of cigarettes daily: 21 or more > sample size 
than 20 or less
(% valid value)
4 weeks
Bauld L et al.11 2009 Clinical 
controlled trial
1785 members 
of the public
Age range: 16 or above
Male proportion: 41.5%
No. of cigarettes daily: 21 or more
(Represents: 40.6%)
4 weeks
Maguire et al.12 2001 Randomised 
controlled
trial
484 patients Age range: 18 or above
Male proportion: 58.1%
Not pregnant women
No. of cigarettes daily: not a minimum no.
12 months
Sinclair et al.13 1998 Clusters 
Randomised 
controlled trial
492 patients Age range: 17-77
Male proportion: 37%
No. of cigarettes daily: 21 or more
9 months
Anderson et al.14 1995 Randomised 
controlled
trial
40 pharmacies A 21-year-old researcher visited 40 pharmacies 
divided into two groups. The research assessed:
– How busy the pharmacy was
– The willingness of the pharmacist to help
– General satisfaction with the consultation and 
   overall communication
5 days course
148 Citations were not included
based on abstracts: 
- Irrelevant topic 
(e.g. Hypertension,
Dyslipidaemia, 
General overview
on prevention of CVD) 
37 Full - text articles
evaluated for eligibility
This review article contained
6 eligible studies
31 Full articles were
not included as:
- Reviews
- Not in UK
- Not in English Language
- Not specifically based in
 community pharmacy 
302 citations identified and screened
through database search
185 citations screened by abstracts
25 duplicates removed
92 citations omitted because of title
Figure 1. Flow chart demonstrating the as-
sessments of articles included in this review.
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cessation service versus a control group, one evaluat-
ed both the interventions and the cost-effectiveness 
mechanisms of the services, and two analysed the 
training offered for pharmacists and pharmacy staff.
Table 2. UK study objectives, interventions and outcomes.
Author(s) Objectives/ Interventions Key Findings/Statistics p
Bauld et al.16 Two groups set:
• 1st group: one-to-one counselling 
with a pharmacist
• 2nd group: group-based support
CO-validated quitters consolidated drop in CO levels from 
22.5% at 4 weeks monitoring period to 3.6% at 52 weeks of 
the first quitting date.
1st group: 2.8% cessation rates 
2nd group: 6.3%
Cost effectiveness per group:
Probability of quitting: 1st group: 0.0025 and 2nd group: 0.055
Cost per client: 1st group: £79, 2nd group: £368
1st group: an incremental cost per QALY of £2600
2nd group cost per QALY: £4800
<0.001
Boyd et al.15 Two groups set:
• 1st group: Pharmacy-based therapy
• 2nd group: Group therapy
Cost effectiveness:
1st group: Cost per participant: £53.31 (probability to quit: 
0.17)
2nd group: Cost per participant: £338.54 (probability to quit: 
0.31)
NA*
Bauld et al.11 Two groups set:
• 1st group: Pharmacy-based service
• 2nd group: Group therapy
CO-validated quitters (CO range 1-10 ppm.):
1st group: 18.6%
2nd group: 35.5%
Self-reported quitters:
1st group: 9.2%
2nd group: 5.8%
<0.0005
Maguire et al.12 Two groups:
• 1st group: Pharmacy-based smoking 
cessation (PAS)
• 2nd group: as control
Non-stop continuous abstention of smoking:
3 months PAS group:27.5%
Control group:11%
6 months PAS group:18.5%
Control group:8.2%
12 months (cotinine <50 
ng/mL)
PAS group:14.3%
Control group:2.7%
<0.001
Sinclair et al.13 Two groups:
• 1st group: Trained pharmacists and 
pharmacy assistants
• 2nd group: as control
Smoking cessation acceptance:
1 month 1st group: 29.9%
2nd group: 23.6%
4 months of quitting 1st group: 16.1%
2nd group: 10.9%
9 months of quitting 1st group: 12.0%
2nd group: 7.4%
0.12
0.094
0.089
Anderson et al.14 Two groups:
• 1st group: 20 random Barnet 
pharmacists, who participated in a 
training session.
• 2nd group: contained 20 untrained 
pharmacists
Time spent: 1st group: 5.3 min (SD 4.7)
2nd group: 2.45 min (1.3)
Questions asked: 1st group: 20
2nd group: 16
χ2=3.956 (df=1)
Referral to doctor: 1st group > 2nd group
χ2=3.956 (df=1)
Unwillingness to help: 1st group: 1 pharmacist
2nd group: 5 pharmacists
<0.02
<0.05
<0.05
<0.05
*NA – not available. 
QALY – quality-adjusted life year.
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Evaluation of training interventions and outcomes of 
smoking cessation services delivered by community 
pharmacies
Bauld et al11 defined two groups using a Maudsley 
model. The first group included pharmacy-based ser-
vices with one-to-one support once a week, which last-
ed between 5 and 15 minutes depending on the indi-
vidual, combined with NRT supply. The second group, 
which involved group support, offered behavioural 
support and education as well as 60-minute counselling 
by a specialist, in combination with NRT, bupropion 
or varenicline. The duration of the services provided 
to each group was 7 weeks and 12 weeks, respectively 
(Table 2). The study established that there was a sta-
tistically significant difference in the abstinence rate at 
4 weeks (p<0.0005) between carbon monoxide (CO)-
validated and self-reported quitters. In this compari-
son, smokers who quit by themselves and those with 
CO greater than 10 ppm were excluded.
Maguire et al12 compared two groups. The phar-
macy-based smoking cessation service (Pharmacists’ 
Action on Smoking; PAS) and a second group, which 
acted as a control. In the PAS group, the pharma-
cist had an introductory one-to-one interview with 
a patient, which lasted between 10 and 30 minutes, 
presenting the PAS chart and leaflets, and setting a 
weekly monitoring plan for a total of 4 weeks, then 
once a month for 3 months. NRT was not always 
offered. The control group was offered typical ser-
vices, i.e. the pharmacists dispensed smoking cessa-
tion treatment without any consultation. The results 
showed that 27.5% of the clients who used the phar-
macy-led service managed to refrain from smoking 
for the whole period, whereas only 11% of the clients 
who participated in the control group maintained 
their abstinence. The duration of abstinence for both 
groups was 3 months. Furthermore, the prevalence 
of abstinence in both groups during a 6-month peri-
od was 18.5% for the pharmacy-led group and 8.2% 
for the control group. At 12 months, the percentage 
of urinary cotinine-validated continuous abstinence 
was 14.3% in the pharmacy-led group and 2.7% in the 
control group (p<0.001).
A study by Sinclair et al13 had two groups, the 
first of which consisted of trained pharmacists and 
pharmacy assistants who provided the pharmacy sup-
port programme, including enrolment in the advice 
service and record-keeping, while the second group, 
which was the control, were offered essential ser-
vices such as dispensing of NRT. The results of both 
groups for self-reported abstinence were obtained af-
ter 1 month, 4 months, and 9 months. The results es-
tablished that in the first month, the pharmacy sup-
port program group (requiring enrolment, advice-
counselling and record-keeping) reached 29.9% ab-
stinence whereas the control group had 23.6% absti-
nence (p=0.12). After 4 months, the results showed 
that the pharmacy support program achieved ab-
stinence for 16.1% of the participants, compared 
to 10.9% for the control group (p=0.094). Finally 
12.0% of the pharmacy led group and 7.4% of the 
control group (p=0.089) achieved abstinence for the 
9-month period. Although the pharmacy-led group 
showed higher abstinence, this was not statistically 
significant.
Anderson et al14 evaluated two groups. The first 
group contained 20 random pharmacies in the Lon-
don borough of Barnet. The Barnet pharmacists were 
trained by attending a five-day session, including a 
two-day course that covered techniques for personal 
interaction and promotion of public health, as well 
as the communication expertise needed to put over 
the health education message, and a one-day continu-
ous course. An active pharmacist working in the com-
munity setting and a psychologist taught the course. 
During the five day courses Barnet pharmacists had 
the opportunity to learn about diabetes, coronary 
heart disease, nutrition, etc. In general, the course 
stimulated participation and was based on compe-
tence and knowledge acquired through a communica-
tion process. The second group included 20 untrained 
pharmacists. In both groups the researcher, who was 
the customer, asked for information about available 
patches for quitting smoking. The results showed that 
the time spent by each group on assessing the custom-
er (researcher) was dependent on training. Thus, the 
mean time spent was 5.3 minutes for the first group 
and 2.45 minutes for the second group (p<0.02). This 
significant difference arose from the fact that Bar-
net pharmacists, who had already trained in order 
to offer the smoking cessation service, took more 
time to assess the patient. Furthermore, regarding 
the questions that both groups were asked, the results 
showed that 20 (all) Barnet pharmacists and 16 out of 
20 untrained pharmacists first asked about the quan-
tity of cigarettes that the researcher smoked per day 
(p<0.05). Referral to a doctor is another important 
element of smoking cessation services, as each indi-
vidual has to be treated differently. In this study the 
researcher declared that she was diabetic—referral 
is compulsory when a diabetic patient wants to quit 
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smoking. Results established that a larger percent-
age of Barnet pharmacists referred the customer (re-
searcher) to a doctor compared to control pharma-
cists (p<0.05). The study pointed out that there was 
no difference between the groups regarding how busy 
the pharmacies were. Nevertheless, only one Barnet 
pharmacist was reluctant to counsel the customer (re-
searcher) compared with five pharmacists from the 
control group (p<0.05).14
Evaluation of cost-effectiveness outcomes of smoking 
cessation services
Boyd et al15 defined two groups using a Maudsley 
model. The first group received a pharmacy-based 
service with one-to-one support once a week com-
bined with a supply of NRT. The second group un-
derwent group therapy in the community, rather than 
in pharmacies, in combination with smoking cessa-
tion medication. The individual pharmacy-led service 
demonstrated better results in terms of the number 
of clients who stopped smoking compared to group 
services run in the community. The outcomes, which 
were applicable to the cost-effectiveness analysis, 
were based on the original sample of participants and 
the quitters who were CO-validated at 4 weeks after 
quitting. The pharmacy-led group had 255 quitters, 
whereas the group service led by a specialist involved 
146 quitters. The authors also estimated the probabil-
ity of stopping smoking within a period of four weeks 
as an outcome of this study. The probability for the 
pharmacy-led group was 0.17 whereas for the group-
based service it was 0.31. Reviewing the results re-
lated to the probability of quitting smoking for each 
group, the group-based service had the highest prob-
ability of cessation success in four weeks, but at the 
same time proved to be the more expensive interven-
tion, as the cost per client was £338.54 compared to 
£53.31. Overall, the pharmacy-led service required an 
incremental cost of £772 per quitter for the four-week 
programme, while the group-based service required a 
supplementary cessation cost of £1612.
Evaluation of both cost-effectiveness and clinical 
outcomes of smoking cessation services
Another study by Bauld et al16 included two groups, 
building on their intervention based on the Maudsley 
model, in order to determine the outcomes and the 
cost-effectiveness of pharmacy-based smoking cessa-
tion services. The aim of this study was to test the quit 
rates and the cost-effectiveness of the behavioural 
support in both groups who were offered the ser-
vice. The first group had one- to-one counselling with 
a pharmacist and the second received group-based 
support. The duration of the programme was 12 and 
7 weeks, respectively. Both groups were compared 
with the self-quit rate. Generally speaking, CO-vali-
dated quitters consolidated a drop in CO levels from 
22.5% at 4 weeks to 3.6% at 52 weeks after the quit 
date. The first group achieved 2.8% cessation rates 
whereas the second group achieved 6.3% (p<0.001). 
Concerning the financial effectiveness in both groups, 
the results suggested that the first group had a cost 
per client of £79.20, compared to £368 in the second 
group. The pharmacy-led service required a further 
cost of £7800 for the 52-week quitting programme; 
however, the group-based service required a supple-
mentary quitter cost of £9200. The probability of quit-
ting smoking was 0.025 in the first group and 0.055 in 
the second group, compared with 0.015 in the “self-
quit” group. Finally, the pharmacy-led service had 
an incremental cost per quality-adjusted life year of 
£2600, compared with £4800 for the group-based ser-
vice.
Study quality evaluation
This review assessed a total of 6 studies, which includ-
ed two observational studies and four randomised 
controlled trials. After evaluating the studies included 
in this report, it is worth mentioning that the study of 
Sinclair et al13 was the only one that proposed calcu-
lating sample sizes; however, it is not clear whether 
the methods proposed were actually considered. Fur-
thermore, there is no obvious evidence that most of 
the studies included had the capacity to compare and 
contrast the groups with each other. However, it must 
be acknowledged that one of the six studies covered 
(Maguire et al12) had a large number of participants. 
Only Anderson et al14 used blinding in the study. This 
meant that the researcher/customer did not know 
which pharmacists had participated in the 5-day train-
ing course before offering the smoking cessation ser-
vice. The other studies included did not use blinding 
in their methods, because the intervention made its 
use difficult.
Comparing the studies included, Maguire et al,12 
Sinclair et al,13 and Anderson et al14 trained the phar-
macists and pharmacy personnel who managed the 
interventions before offering the services. Maguire 
et al12 stated that full instructions, advice and pro-
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posals were provided to pharmacists and pharmacy 
staff concerning smoking cessation in order to edu-
cate them and to help them to be ready to offer the 
intervention. Subsequently, they organised workshops 
for them, of three hours’ duration, in order to teach 
them about smoking cessation guidelines in addition 
to the experimental procedure of the study. These 
workshops were run by specialists and took place 2-3 
weeks after the distribution of instructions through a 
written proposal. Statistical analysis of smoking, prev-
alence, NRT products, as well as instructions regard-
ing the application and the explanation of the PAS 
model, were some of the topics covered in the work-
shop. All pharmacists and pharmacy staff had support 
and the opportunity to ask any questions regarding 
the PAS model. Sinclair et al13 trained pharmacists 
and pharmacy staff in a 2-hour tutorial. This session 
informed them about the steps of modification with 
regard to smoking cessation and communication ser-
vices for assigning change and delivering continuous 
assistance. The study by Anderson et al14 included 
two training sessions (five days in total). A session 
was run for two days, which included education with 
reference to communication abilities, and key points 
on how to promote health, presented by an active 
pharmacist working in the community setting. The 
second part of the training comprised a continuous 
program of one-day sessions on particular subjects 
taught by a psychologist.
Finally, only in the study by Maguire et al12 were 
information and instructions provided pertaining to 
the services offered. None of the studies mentioned 
supervision of any person who provided the interven-
tion, nor was there any information regarding corrob-
oration of the intervention technique.
Discussion
A review of all the results mentioned above shows 
that Bauld et al11 and Sinclair et al13 found signifi-
cant results for abstinence from smoking over a pe-
riod of six months, whereas after that period the re-
sults showed no significant difference (e.g. after nine 
months). Furthermore, all studies included in this re-
view used the same methodology. More specifically, 
they compared a pharmacy-led service to a control.
Certain studies covered in the review stated the 
hypothesis set, although behaviour change techniques 
were not defined. Bauld et al8 did not state the hy-
pothesis of behavioural change techniques in the ac-
tions conducted. Although Maguire et al12 mentioned 
that the intervention was based on PAS, no more de-
tails of behavioural modification were included. Sin-
clair et al13 educated pharmacists and pharmacy staff 
in the steps of modification so as to allow them to 
evaluate clients’ progress and give personalised sup-
port to the clients’ existing status. Nevertheless, the 
methods of the behavioural modification achieved 
did not take into account the modifications in the be-
haviour of the clients when being advised by the phar-
macists and pharmacy staff.
After six months of monitoring, results have 
shown the valuable impact of pharmacists and phar-
macy staff contributing to smoking cessation services. 
Pharmacists as healthcare professionals and the phar-
macy personnel had the ability to offer counselling, 
education and behavioural support to patients who 
wished to quit smoking.12 Most of the studies covered 
in this review operated multifaceted interventions in-
cluding various mechanisms. Bauld et al11 assessed 
the services in terms of their content and methodol-
ogy, using one-to-one interviews in comparison with 
group treatment.
In the studies included in this review, different 
comparison procedures were conducted. The study by 
Bauld et al11 included active treatments. It compared 
non-medication approaches with the total number of 
patients taking NRT. A barrier that may have to be 
overcome is that the routine collection of data is im-
portant for checking and assessing smoking cessation 
programmes; however, Maguire et al12 stated that 
there is a lack of record keeping in monitoring period 
measures.
Regarding the encouragement of abstinence from 
smoking, Bauld et al,11 Maguire et al,12 and Sinclair 
et al13 mentioned that most of the participants who 
wanted to stop smoking, either by proposing a quit 
date or attempting to quit, were looking for help from 
smoking cessation medications. Furthermore, Sinclair 
et al13 stated that pharmacy staff’s lack of time of af-
fected patients’ compliance regarding the pharmacy-
led service, which caused non-attendance at the ser-
vice.
Although pharmacy-led services showed positive 
results for smoking cessation, in reality there was a 
lack of time for all contributors (either participants or 
pharmacists-pharmacy staff), as clarified by Maguire 
et al12 and Sinclair et al.13 In addition, a remunera-
tion issue covering the smoking cessation programs 
was raised as a large obstacle for pharmacists in or-
der to successfully offer the smoking cessation servic-
es, as identified by both Maguire et al12 and Ander-
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son et al.14 According to these studies, pharmacists 
were not very eager to offer further advice regarding 
smoking cessation, with the exception of medication, 
as they were not paid for the extra work related to 
this service. An additional problem is the absence of 
training, which leads to a lack of self-confidence, thus 
causing problems in communication with patients 
and reducing the quality of the services offered.12 Al-
though training in offering a smoking cessation ser-
vice has been provided for pharmacists since 1995, 
there is still a need for more scheduled sessions with 
specialists, such as psychotherapists or specialised 
pharmacists. As stated in the report of Anderson et 
al,14 pharmacists mainly gave advice to patients re-
garding medication for smoking cessation. However, 
in the studies reviewed, pharmacists not only offered 
advice on medication, but also delivered initial coun-
selling to each individual in order to understand their 
needs. Maguire et al12 also emphasised that the rela-
tionship between pharmacists and physicians needs 
improvement, as this is a barrier that affects the de-
livery of smoking cessation services. They concluded 
that patient care should not be affected by the lack of 
effective communication between GPs and pharma-
cists. Hence, healthcare professionals should work as 
a team for the benefit of the patient.
Cost effectiveness analysis of the studies carried 
out by Boyd et al15 and Bauld et al16 showed that both 
pharmacy-led services and group services were fi-
nancially cost-effective, even though they had a low 
cessation rate at one year. A pharmacy-led service 
achieved lower cessation rates compared to the group 
service, whereas group services were more expensive 
than pharmacy-led services. On the whole, clients 
had better results at four weeks but some patients’ re-
lapsed, leading to a lower abstinence rate after one 
year. Based on the results, it is important to increase 
the number of smokers who use the smoking cessa-
tion pharmacy-led service, as it is cost-effective. Fur-
thermore, the pharmacy offers patients education, 
counselling, and behavioural change that is easily ac-
cessible. Finally, since an important factor leading to 
the relapse of smoking is stress, pharmacists are able 
to support patients in order to improve their quality 
of life and to encourage ongoing cessation.12-14
Conclusion
Health care professionals such as pharmacists can 
run effective smoking cessation services, leading to a 
decreased level of morbidity and premature mortal-
ity associated with smoking-related chronic diseases, 
as well as an augmentation of work productivity. In 
spite of smoking cessation services being the “gold 
standard” concerning cardiovascular disease preven-
tion, they are not routinely offered by pharmacists 
and other health care professionals, as the training 
is still inadequate. In order to increase the success 
rates of pharmacy-led smoking cessation services, ed-
ucation and routine training for all pharmacy person-
nel is essential. Furthermore, it is imperative to con-
sider the time constraints of the pharmacy personnel, 
as well as adequate reimbursement, to facilitate ser-
vice provision. Results have shown that pharmacists, 
as primary healthcare professionals, are able to of-
fer advice, help and support for smoking cessation 
with a higher success rate compared to self-quitting. 
The cost is relatively high, but at the same time such 
programmes are effective, using both pharmacy-led 
and group-led services. However, the pharmacy-led 
service is less expensive than group-based ones. It is 
thus imperative to try to increase both pharmacists’ 
and patients’ awareness of pharmacy-led smoking 
cessation services, and to ensure that these services 
become routinely offered in the community pharma-
cy setting.
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